SONN vs. LPTX, MIRA, OKUR, COCP, NNVC, GLYC, MRKR, ATHA, MEIP, and QNTM
Should you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Leap Therapeutics (LPTX), MIRA Pharmaceuticals (MIRA), OnKure Therapeutics (OKUR), Cocrystal Pharma (COCP), NanoViricides (NNVC), GlycoMimetics (GLYC), Marker Therapeutics (MRKR), Athira Pharma (ATHA), MEI Pharma (MEIP), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry.
Sonnet BioTherapeutics vs.
Sonnet BioTherapeutics (NASDAQ:SONN) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership.
Leap Therapeutics received 274 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 83.33% of users gave Sonnet BioTherapeutics an outperform vote while only 68.53% of users gave Leap Therapeutics an outperform vote.
In the previous week, Sonnet BioTherapeutics had 3 more articles in the media than Leap Therapeutics. MarketBeat recorded 3 mentions for Sonnet BioTherapeutics and 0 mentions for Leap Therapeutics. Sonnet BioTherapeutics' average media sentiment score of 0.00 equaled Leap Therapeutics'average media sentiment score.
Sonnet BioTherapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.
9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Comparatively, 5.4% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Sonnet BioTherapeutics has higher revenue and earnings than Leap Therapeutics.
Sonnet BioTherapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 1,288.89%. Leap Therapeutics has a consensus price target of $4.92, suggesting a potential upside of 923.88%. Given Sonnet BioTherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sonnet BioTherapeutics is more favorable than Leap Therapeutics.
Leap Therapeutics' return on equity of -116.24% beat Sonnet BioTherapeutics' return on equity.
Summary
Sonnet BioTherapeutics beats Leap Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Sonnet BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonnet BioTherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SONN) was last updated on 2/22/2025 by MarketBeat.com Staff
